Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555697 · ClinicalTrials.gov registry record · Phase 1
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01555697 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 80 participants.
The verdict
NCT01555697, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
Cognitive training is moderately effective at reducing symptoms and improving life function in schizophrenia patients. The present application develops a strategy for increasing the effectiveness of cognitive training through the use of pro-cognitive medications. Specific biomarkers will be studied that identify patients most sensitive to these pro-cognitive medications, to test the feasibility of using these biomarkers in a large clinical trial of medication-enhanced cognitive training in schizophrenia.
Interventions
- DRUG Placebo
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555697
The ClinicalTrials.gov registry entry for NCT01555697 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01555697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555697 about?
NCT01555697 is a clinical study titled "Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia". Cognitive training is moderately effective at reducing symptoms and improving life function in schizophrenia patients. The present application develops a strategy for increasing the effectiveness of cognitive training through the use of pro-cognitive medications. Specific biomarkers will be studied ...
What is the current status of trial NCT01555697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2014-07. Estimated completion is 2019-06-01.
What interventions are being tested in trial NCT01555697?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT01555697?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.